 |
|
|
|
 |
|
|
| Article 1 to 10 out of 29 concerning Evotec AG
|
-
Evotec Reports Start of Phase II Proof-of-Concept Quit Rate Study with EVT 302 and Results of Craving Study
(12 Sep 2008)
Evotec AG announced the start of the Phase II proof-of-concept study, investigating the effect of EVT 302 on the quit rate of patients who want to stop smoking. The Company also provided an analysis of the results of its exploratory Phase II craving ...
-
Evotec Announces Initiation of Phase I Clinical Trial of VR1 Antagonist under Partnership with Pfizer Inc.
(05 Aug 2008)
Evotec AG announced that dose escalation studies for a Phase I clinical trial of a small molecule VR1 (vanilloid receptor 1) antagonist is being progressed by Pfizer Inc. under the collaboration with Evotec. The Phase I study is a randomised, ...
-
DIREVO announces transfer of patents from Evotec
(11 Jul 2008)
DIREVO Biotech AG announced that it has entered into an agreement with Evotec under which Evotec will transfer certain patents to DIREVO that are currently licensed by DIREVO. Such patents protect key components of DIREVO's unique and proven ...
-
Evotec's EVT 101 well tolerated in four week higher repeat dose safety study
(07 Jul 2008)
Evotec AG announced top-line results of a double-blind, 4-week Phase Ib study with EVT 101, an orally active NR2B-subtype selective antagonist of NMDA receptors with potential in Alzheimer's disease, neuropathic pain and other indications. The study ...
-
Evotec Provides Update on Planned NASDAQ Listing in the Context of its Announced Acquisition of Renovis
(11 Jan 2008)
Evotec AG provided further details on its planned NASDAQ listing in the context of the anticipated acquisition of Renovis Inc. Evotec AG has filed a registration statement on Form F-4 to register with the US Securities and Exchange Commission (SEC) ...
-
Evotec Completes Divesture of Chemical Development
(04 Dec 2007)
Evotec AG announced that it has completed the sale of its Chemical Development Business to Aptuit, Inc. for a total consideration of £ 31.5 million (approx. EUR 44 million) effective November 30, 2007. According to the company, this divestiture ...
-
Evotec to Acquire Renovis
(21 Sep 2007)
Merger to Create Emerging Pharmaceutical Company
Evotec AG and Renovis, Inc. announced that they have entered into a definitive agreement under which Evotec will acquire Renovis, a biopharmaceutical company focused on the discovery and development of drugs for major medical needs in the areas of ...
-
Evotec to Launch its First Innovation Centre for Fragment Based Drug Discovery
(24 May 2007)
Evotec AG announced the launch of its Innovation Centre for Fragment Based Drug Discovery ('FBDD'). FBDD offers an alternative approach for identifying novel, small molecule hits (fragments) for a number of biological targets including those that ...
-
Evotec Initiates its First Phase I Clinical Study with EVT 302
(28 Mar 2007)
Evotec AG announced the initiation of its first Phase I study with EVT 302. This open-label study is designed to access the occupancy of the monoamine oxidase B enzyme (MAO-B) in brain after administration of single oral doses of EVT 302 by the use ...
-
Evotec Reaches Second Milestone and Receives Success Payment in Alzheimer's Disease Collaboration with Takeda
(17 Aug 2006)
Evotec AG announced that the second milestone has been achieved in its four-year drug discovery collaboration with Takeda Pharmaceutical Company Limited. Evotec has granted Takeda exclusive rights to a novel target in Alzheimer's disease based on ...
Additional information
Evotec AG
Hamburg, Germany
Company
|
|
|
|
|
|
Top
